Abraham Van Wyk

Abraham van Wyk brings more than 15 years of clinical research industry experience to his role as FHI Clinical SA’s Managing Director. Abraham previously served as the CEO of Triclinium Clinical Development (TCD) Global, where he executed the company’s acquisition by FHI Clinical.

While managing the TCD Group of companies, van Wyk led the M&A strategy, which included the acquisition of HeXor (now Value in Research), a health economics and outcomes research company, as well as being the co-founder of an eClinical solutions company (now NuvoteQ) and establishing TCD Global as a full-service CRO specializing in infectious disease and vaccine research across sub-Saharan Africa. The TCD Group of companies was sold to EOH (JSE Listed Group).

Abraham previously held the position of Managing Director of Africa at Cytespace Research (acquired by Premier Research). Prior to that position, Abraham established the East African region for Quintiles (now IQVIA) and managed the East and West African operations as Regional Head.

Abraham serves on the board of several biotech, medical device and medtech companies, including AMR-focused Bugworks; Burl Concepts, a medical device company; and NuvoteQ, an eClinical solutions company, among others.

Abraham holds a bachelor’s degree in medical sciences and a bachelor’s (Hons) degree in cellular biology from the University of Pretoria, in addition to an MBA from the University of South Africa.